Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer.
Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer.
复制标题
术前贝伐单抗联合紫杉醇和卡铂治疗可手术切除的非小细胞肺癌。
DOI：
10.1016/j.athoracsur.2010.07.047
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Otterson,GregoryA
中科院分区：
文献类型：
--
作者：
Bertino,Erin;Villalona-Calero,MiguelA;Ross,Patrick;Grever,Michael;Otterson,GregoryA
Preoperative chemotherapy is established for stage III (N2 positive) non-small cell lung cancer (NSCLC) and has demonstrated benefit in two studies. In both studies, survival was improved for patients who received chemotherapy (5-year survival 53% vs 24%[1], and median survival 26 vs 8 months [2]). Recently, Pisters and colleagues [3] reported the results of S9900, a trial of preoperative chemotherapy, followed by surgical resection, compared with surgical resection alone in earlier stage NSCLC [3]. Although this trial was stopped before full accrual, it showed a trend toward improved survival in the preoperative chemotherapy arm.Bevacizumab, an antibody directed to vascular endothelial growth factor, has improved response rates and overall survival when combined with chemotherapy for patients with metastatic lung cancer and is being tested in the adjuvant setting with chemotherapy [4]. Several important toxicities, including bleeding, tracheoesophageal fistulas, and wound healing complications, affect the utility of bevacizumab in the perioperative setting [5].
